

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7872 - NOVARTIS / GSK (OFATUMUMAB AUTOIMMUNE INDICATIONS)

SECTION 1.2

Description of the concentration

1. This notification is submitted on behalf of Novartis AG (“Novartis”), which intends to acquire the rights to the Autoimmune Indications owned by GlaxoSmithKline Plc (“GSK”) with respect to the monoclonal antibody drug ofatumumab, none of which are approved for use or will be approved before 2021 at the earliest (the “Proposed Transaction”).
2. At this stage, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation, pursuant to Article 5(2) second subparagraph thereof.